Cargando…

Transgender Women’s Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP)

Long-acting injectable cabotegravir (CAB-LA) is in advanced stages of clinical trials. Under the standard protocol, CAB-LA is injected into the gluteal muscle by a healthcare provider every eight weeks. To explore transgender women’s barriers and facilitators to tailored delivery strategies—includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rael, Christine Tagliaferri, Lopez-Ríos, Javier, McKenna, Stacey A., Das, Doyel, Dolezal, Curtis, Abascal, Elena, Carballo-Diéguez, Alex, Schnall, Rebecca, Hope, Thomas J., Bauermeister, José, Bockting, Walter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254438/ https://www.ncbi.nlm.nih.gov/pubmed/34216284 http://dx.doi.org/10.1007/s10461-021-03357-y

Ejemplares similares

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women
por: Donnell, Deborah, et al.
Publicado: (2023)

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020)

1547. Integrating Long-acting Injectable Cabotegravir for PrEP into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex with Men: Results from the PILLAR & EBONI Studies
por: Valenti, William M, et al.
Publicado: (2023)

1531. Early Real-World Experience of Long-Acting Cabotegravir (CAB) for HIV Pre-Exposure Prophylaxis (PrEP) in a Large Community-Based Clinic Network (CAN Community Health): Utilization and PrEP Persistence
por: Altamirano, Jessica A, et al.
Publicado: (2023)

1550. Engaging Black Women on Cabotegravir LA for PrEP by Optimizing Novel Implementation Strategies (EBONI) Study: Provider Perceptions of Appropriateness of Cabotegravir LA for PrEP for Cis-and-Trans Black Women
por: Richmond, Teriya, et al.
Publicado: (2023)

Predictors of PrEP awareness, PrEP discussion and interest in long‐acting injectable PrEP among Filipina transfeminine adults
por: Restar, Arjee Javellana, et al.
Publicado: (2023)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

Commentary: the value of PrEP for people who inject drugs
por: Coleman, Rosalind L, et al.
Publicado: (2016)

Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users
por: Smith, Dawn K., et al.
Publicado: (2013)

PrEP discontinuation among Latino/a and Black MSM and transgender women: A need for PrEP support services
por: Nieto, Omar, et al.
Publicado: (2020)

973. PrEP Care Continuum among Transgender Women at a Patient-Centered PrEP Program in Atlanta, GA
por: Aldredge, Amalia, et al.
Publicado: (2020)

2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies
por: Patel, Parul, et al.
Publicado: (2019)

The relationship of PrEP beliefs to perceived personal, interpersonal and structural benefits and barriers to PrEP use in women who inject drugs
por: Paulus, Kirsten, et al.
Publicado: (2023)

1553. Cost Effectiveness of Cabotegravir versus Continuous and Event-Driven PrEP: A Systematic Review and Cost-Analysis
por: Sharma, Ishani, et al.
Publicado: (2023)

To switch or not to switch: Intentions to switch to injectable PrEP among gay and bisexual men with at least twelve months oral PrEP experience
por: Meyers, Kathrine, et al.
Publicado: (2018)

Study protocol for an efficacy trial of the “PrEP for Health” intervention to increase HIV PrEP use among people who inject drugs
por: Bazzi, Angela R., et al.
Publicado: (2023)

198 Meta-analysis of Transgender Exclusion from PrEP Clinical Trials
por: Lee, Jeremiah
Publicado: (2023)

More than just oral PrEP: exploring interest in rectal douche, dissolvable implant, removable implant and injection HIV prevention approaches among racially diverse men who have sex with men in the Northeast Corridor
por: Martinez, Omar, et al.
Publicado: (2022)

Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study
por: Rael, Christine Tagliaferri, et al.
Publicado: (2020)

1559. Healthcare Staff Perceptions of Feasibility and Acceptability on Implementing Injectable HIV Pre-exposure Prophylaxis into Standard of Care: Baseline Results from the PrEP Implementation Study for Cabotegravir Long Acting for Men in the Real World (PILLAR)
por: Torres, Julian A, et al.
Publicado: (2023)

Uptake, Retention, and Adherence to Pre-exposure Prophylaxis (PrEP) in TRIUMPH: A Peer-Led PrEP Demonstration Project for Transgender Communities in Oakland and Sacramento, California
por: Sevelius, Jae M., et al.
Publicado: (2021)

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
por: Marzinke, Mark A., et al.
Publicado: (2023)

Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis
por: Stansfield, Sarah E., et al.
Publicado: (2023)

PrEP interest and HIV‐1 incidence among MSM and transgender women in coastal Kenya
por: Kimani, Makobu, et al.
Publicado: (2019)

The importance of PrEP persistence in preventing HIV infections on PrEP
por: Spinelli, Matthew A, et al.
Publicado: (2020)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

1285. PrEP Acceptability, Uptake, and Adherence Among Young Men Who Have Sex with Men and Transgender Women in PrEP Demonstration Project, Chiang Mai, Thailand
por: Kaewpoowat, Quanhathai, et al.
Publicado: (2019)

“PrEP”ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women
por: Pasipanodya, Elizabeth C., et al.
Publicado: (2021)

“Free Testing and PrEP without Outing Myself to Parents:” Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men
por: Fisher, Celia B., et al.
Publicado: (2018)

PrEP-RN: Clinical Considerations and Protocols for Nurse-Led PrEP
por: O'Byrne, Patrick, et al.
Publicado: (2019)

1287. PrEP-Engaged or PrEP Curious?: A Characterization and Comparison of Initial PrEP Appointment Attenders vs. Nonattenders
por: Kahal, Deborah A, et al.
Publicado: (2019)

The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices
por: Sevelius, Jae M, et al.
Publicado: (2016)

PrEP Use Awareness and Interest Cascade among MSM and Transgender Women Living in Bali, Indonesia
por: Cempaka, Rissa, et al.
Publicado: (2020)

Determinants of Pre-exposure Prophylaxis (PrEP) Implementation in Transgender Populations: A Qualitative Scoping Review
por: Zamantakis, Alithia, et al.
Publicado: (2022)

“Entre Nosotras:” a qualitative study of a peer-led PrEP project for transgender latinas
por: Zamudio-Haas, Sophia, et al.
Publicado: (2023)

Slow Uptake of PrEP: Behavioral Predictors and the Influence of Price on PrEP Uptake Among MSM with a High Interest in PrEP
por: van Dijk, Mart, et al.
Publicado: (2021)

Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida
por: Jo, Young, et al.
Publicado: (2020)

Low Knowledge of HIV PrEP Within a Midwestern US Cohort of Persons who Inject Drugs
por: Sayood, Sena, et al.
Publicado: (2021)

Provider Implicit Bias in Prescribing HIV Pre-exposure Prophylaxis (PrEP) to People Who Inject Drugs
por: Dubov, Alex, et al.
Publicado: (2023)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_92m9kohuous7khpfn1vnil8mfv